Skip to main content
Abbisko Cayman Limited logo

Abbisko Cayman Limited — Investor Relations & Filings

Ticker · 2256 ISIN · KYG0028A1085 LEI · 655600UAX2YV03PRXN31 HKEX Manufacturing
Open in API
Filings indexed 402 across all filing types
Latest filing 2025-08-27 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 2256

About Abbisko Cayman Limited

http://www.abbisko.com

Abbisko Cayman Limited is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule therapies. The company leverages a robust in-house R&D engine and a multi-dimensional discovery platform to advance a rich pipeline focused primarily on oncology, encompassing both precision-oncology and immuno-oncology candidates. Key product candidates include pimicotinib, which has shown positive topline results for the treatment of tenosynovial giant cell tumor (TGCT). Abbisko aims to develop novel treatments that address critical unmet medical needs for patients globally.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Returns
Transaction in Own Shares Classification · 1% confidence The document is a regulatory listing return (Form FF305) filed under the Hong Kong Stock Exchange listing rules, detailing changes in issued shares, treasury shares, and an on-market share repurchase program (e.g., dates, volumes, prices, confirmation sections). It is a report of the company’s repurchase of its own shares, which corresponds to the “Transaction in Own Shares” category.
2025-08-27 English
VOLUNTARY ANNOUNCEMENT - IND CLEARANCE FROM THE CDE FOR ABBISKO THERAPEUTICS' ORAL PD-L1 INHIBITOR ABSK043 IN COMBINATION WITH KRAS G12C INHIBITOR GLECIRASIB FROM ALLIST, FOR THE TREATMENT OF NSC
Regulatory Filings Classification · 1% confidence The document is a voluntary corporate announcement filed with the Hong Kong Stock Exchange regarding IND clearance for a drug candidate. It is not an AGM material, financial report, earnings release, director change, share issuance, or any other specific category. It is a general regulatory announcement outside other defined types and thus falls into the fallback category ‘Regulatory Filings’ (RNS).
2025-08-20 English
Next Day Disclosure Returns
Transaction in Own Shares Classification · 1% confidence The document is an HKEX Form FF305 “Next Day Disclosure Return” detailing changes in issued shares, treasury shares and a repurchase report with trading dates, number of shares repurchased, prices and confirmations of compliance with listing rules. This is a mandatory disclosure of the company’s own share transactions (repurchases and treasury share changes), matching the definition of Transaction in Own Shares (buyback/issuance) rather than a broader financing or governance announcement.
2025-08-20 English
Next Day Disclosure Returns
Transaction in Own Shares Classification · 1% confidence The document is an FF305 “Next Day Disclosure Return” under the Hong Kong Stock Exchange rules, detailing changes in issued shares, treasury shares and the company’s on-market share repurchases and treasury sales. It is a regulatory disclosure of the company’s own share transactions rather than a general financial report, issuance notice or voting announcement. This fits the “Transaction in Own Shares” category (POS).
2025-08-05 English
TERMS OF REFERENCE FOR THE NOMINATION COMMITTEE
Governance Information Classification · 1% confidence The document is the Terms of Reference for the company’s Nomination Committee, detailing the committee’s composition, authorities, duties, meeting procedures, and governance practices. This is an internal governance charter rather than a financial report, earnings release, or regulatory announcement. It fits the definition of a Governance Information filing (CGR), which covers corporate governance rules, board structure, and governance practices.
2025-08-04 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025'. It contains detailed financial statements (Revenue, Gross Profit, R&D expenses, Profit for the period), non-IFRS measures, and a comprehensive Management Discussion and Analysis (MDA) section covering business reviews and clinical pipeline updates. As it provides substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H2 2025
2025-08-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.